Vicki L. Sato - 24 Feb 2026 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Director
Signature
/s/ Vanina de Verneuil, Attorney-In-Fact
Issuer symbol
VIR
Transactions as of
24 Feb 2026
Net transactions value
-$350,436
Form type
4
Filing time
26 Feb 2026, 16:56:28 UTC
Previous filing
03 Feb 2026
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
SATO VICKI L Director C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO /s/ Vanina de Verneuil, Attorney-In-Fact 25 Feb 2026 0001197020

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Options Exercise $62,930 +42,377 +3.7% $1.48 1,186,768 24 Feb 2026 Direct
transaction VIR Common Stock Sale $411,314 -42,177 -3.6% $9.75 1,144,591 24 Feb 2026 Direct F1, F2
transaction VIR Common Stock Sale $2,052 -200 -0.02% $10.26 1,144,391 24 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Options Exercise $0 -42,377 -100% $0.000000 0 24 Feb 2026 Common Stock 42,377 $1.48 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.23 to $10.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 Shares vested and became exercisable in 36 equal monthly installments from October 5, 2017.